MARKET

FTH

FTH

Faeth Therapeutics, Inc
NASDAQ
13.43
-0.06
-0.44%
Opening 09:38 06/16 EDT
OPEN
13.49
PREV CLOSE
13.49
HIGH
13.98
LOW
13.43
VOLUME
7.23K
TURNOVER
--
52 WEEK HIGH
36.76
52 WEEK LOW
5.86
MARKET CAP
18.02M
P/E (TTM)
-0.0941
1D
5D
1M
3M
1Y
5Y
1D
Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG
Dow Jones · 20h ago
BTIG Reiterates Buy on Sensei Biotherapeutics, Maintains $55 Price Target
Benzinga · 20h ago
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership
TipRanks · 1d ago
Sensei Biotherapeutics changes corporate name to Faeth Therapeutics
TipRanks · 1d ago
Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12
Benzinga · 1d ago
Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH
PUBT · 1d ago
SENSEI BIOTHERAPEUTICS - PIKTOR PHASE 1B/2 INTERIM DATA IN HR+/HER2- ADVANCED BREAST CANCER EXPECTED IN 2027
Reuters · 1d ago
Press Release: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Dow Jones · 1d ago
More
About FTH
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The Company's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The Company is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.

Webull offers Sensei Biotherapeutics Inc stock information, including NASDAQ: FTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FTH stock methods without spending real money on the virtual paper trading platform.